Abstract--The physiological effects of retinoic acids (RAs) are mediated by members of two families of nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which are encoded by three distinct human genes, RXR␣, RXR␤, and RXR␥. RARs bind both all-trans-and 9-cis-RA, whereas only the 9-cis-RA stereoisomer binds to RXRs. As RXR/RAR heterodimers, these receptors control the transcription of RA target genes through binding to RA-response elements. This review is focused on the structure, mode of action, ligands, expression, and pharmacology of RXRs. Given their role as common partners to many other members of the nuclear receptor superfamily, these receptors have been the subject of intense scrutiny. Moreover, and despite numerous studies since their initial discovery, RXRs remain enigmatic nuclear receptors, and there is still no consensus regarding their role. Indeed, multiple questions about the actual biological role of RXRs and the existence of an endogenous ligand have still to be answered.
Introduction
The first identified retinoid X receptor (RXR 1 ), referred to as RXR␣ (NR2B1), was initially described as an orphan receptor (Mangelsdorf et al., 1990 ). However, it specifically responded to retinoids because high concentrations of all-trans-retinoic acid (ATRA) could activate RXR␣, leading to the term RXR. Further it was found that 9-cis-retinoic acid (9CRA), an isomer of ATRA, is a high-affinity ligand for RXR␣, as well as for the two additional related subtypes, RXR␤ (NR2B2) and RXR␥ (NR2B3), that were later discovered (Rowe et al. . Despite the fact that 9CRA also displays a high affinity for all three retinoic acid receptors (RARs), RARs exhibit less homology with RXRs than with the thyroid hormone receptor (TR). Indeed, both RARs and RXRs belong to two different groups of the nuclear receptor superfamily, suggesting very different functions . The actual significance of the 9CRA-binding capacity for both RXRs and RARs remains to be established. Importantly, RXRs were also independently identified as factors necessary for efficient binding to DNA of several members of the nuclear receptor superfamily and were shown to form heterodimers with these other nuclear receptors (Laudet et al., 1992 ; . Furthermore, in vitro studies have shown that the RXRs can also form RXR-RXR homodimers, raising the question of the existence of an independent RXR signaling pathway (Mangelsdorf et al., 1991; Mader et al., 1993) . Because of these features, RXRs seem unique among the members of the nuclear receptor superfamily. Moreover, and despite numerous studies since their initial discovery, RXRs remain enigmatic nuclear receptors, and there is still no consensus regarding their role. Indeed, multiple questions about the actual biological role of RXRs and the existence of an endogenous ligand have still to be answered.
Although all these basic questions still remain unanswered or are controversial, it is clear that RXRs are essential players in several pathways because they form many heterodimers and can act as ligand-activated transcription factors. Ligand activation of RXRs has potentially pleiotropic effects on numerous biological pathways and hence therapeutic opportunities, as demonstrated by the clinical use of RXR-selective ligands, referred to as rexinoids, for the treatment of cancer and metabolic diseases (Thacher et 
The RXRs
The three RXR subtypes originate from three distinct genes. For each subtype, several isoforms exist that differ from one another in their N-terminal A/B domain (Chambon, 1996) . There are two major isoforms each for RXR␣ (␣1 and ␣2), RXR␤ (␤1 and ␤2), and RXR␥ (␥1 and ␥2) Liu and Linney, 1993; . So far no functional characterization of these isoforms has been performed.
All three RXR subtypes are common heterodimerization partners for members of the so-called subfamily 1 nuclear receptors (for a review, see ). The first identified heterodimeric partners were the TRs, RARs, and vitamin D receptor (VDR). The peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), farnesoid X receptor (FXR), pregnane X receptor (PXR), and constitutively activated receptors (CARs) are also included in this group. In vitro studies demonstrated that these heterodimers act as ligand-dependent transcriptional regulators by binding to specific DNA-response elements found into the promoter region of target genes and the interaction of RXR increases the DNA-binding efficiency of its partner. Moreover, both in vitro and in vivo approaches have revealed that all these nuclear receptors require RXR as a heterodimerization partner for their function . In addition, RXRs form heterodimers with two members of the small nerve growth factor-induced clone B (NGFIB) subfamily, namely NG-FIB and NURR1, which can also interact with DNA as monomers and homodimers . In most cases, the RXR partner does not exhibit a marked preference for one of the three RXR subtypes.
Importantly, numerous heterodimers that contain RXRs can recognize distinct types of response elements. For instance, RXR-RAR heterodimers bind to a direct repeat of the AGGTCA core motif with a 5-base pair spacing (DR-5) and DR-2, whereas RXR-TR and RXR-LXR bind to DR-4, RXR-VDR and RXR-PXR to DR-3, and RXR-PPAR to DR-1 (for a review, see . Then, the spacing is determinant for the specificity of the binding. Nevertheless, the sequence of the core motif itself, the sequence of the spacer, or that of the flanking nucleotides can also play a role in this interaction. Because RXRs are obligate heterodimerization partners for these nuclear receptors, the number of their potential target genes is tremendous.
RXRs can also form homodimers in vitro that can bind to DNA through DR-1 elements, suggesting the existence of a RXR-specific signaling (Mangelsdorf et al., 1991; Mader et al., 1993) . Interestingly, it has been recently demonstrated that in vivo RXR homodimers could activate PPAR target genes containing a DR-1 (Ijpenberg et al., 2004) . Nevertheless, the question of the existence and the functional role of RXR-RXR homodimers remains open. RXR␣ mutants that exhibit increased homodimerization over heterodimerization capacity could help to address this question in an in vivo setting (Vivat-Hannah et al., 2003) .
No interaction was found between RXRs and the corepressors nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors, suggesting that in absence of ligand RXR-RXR homodimers have a weak repressive activity Zhang et al., 1997) . It is thought that helix 12 of RXRs masks the corepressor binding site of RXRs (Zhang et al., 1999) . Several studies have clearly shown that coactivators can be recruited in presence of an RXR agonist as confirmed by crystal structural investigations (Egea et al., 2002) .
In the context of RXR heterodimers, nuclear receptor partners can be classified into functionally distinct permissive and nonpermissive groups (Leblanc and Stunnenberg, 1995; Shulman et al., 2004). RXR heterodimers that contain permissive partners can be activated by agonists of both RXR and the partner receptor independently or together to induce a synergistic activation. PPARs, LXRs, FXR, and PXR belong to this permissive NR class. In contrast, heterodimers formed by RXR and a nonpermissive partner (RARs, TRs, and VDR) cannot be activated by an RXR agonist but only by the agonist of the partner receptor (Westin et al., 1998). This phenomenon, referred to as "subordination" or "silencing," is not due to an inability of RXR for binding a ligand when the partner is unliganded because several reports have shown that in the context of heterodimers RXR retains the ability to bind a ligand (Cheskis and Freedman, 1996; Thompson et al., 1998; . Rather, nonpermissive partners inhibit RXR activation. However, when the partner is liganded by an agonist or certain antagonists, an RXR agonist can trigger an activation, leading to a synergistic activation through a mechanism that engages a distinct receptor to receptor allosteric signaling pathway (Apfel et bind with low affinity, whereas nonpermissive partners correspond to high-affinity hormone receptors.
Ligands
One the most controversial and unsolved questions regarding RXR research is whether or not endogenous ligands exist and, if so, whether they are able to activate RXRs in vivo. Nevertheless, the role of RXRs in development and the importance of the AF-2 function of RXR␣ was established by knockout experiments . Moreover, studies using reporter transgenic mice based on GAL4DBD-RXRLBD fusion constructs and a ␤-galactosidase reporter gene under the control of Gal binding sites, which allow detection of activated RXR in vivo, revealed the important role played by ligand activation in RXR function. Indeed, RXR was found to be active in specific regions of the spinal cord, suggesting the presence of endogenous ligands (Solomin et al., 1998). All of these results have been confirmed by the use of a comparable system with green fluorescent proteins as reporter (Luria and Furlow, 2004). The search for a natural RXR ligand led to the discovery of 9CRA as a high-affinity ligand for all three RXRs, which also activates the RXR-RXR homodimers Lemotte et al., 1996) . Phytanic acid is present in plasma at micromolar concentrations, which are required for RXR activation. Interestingly, phytanic acid can also activate PPAR␥ (Zomer et al., 2000). Docosahexaenoic acid originates from fish oil and is highly enriched in mammalian brain. Nevertheless, none of these molecules has proven to be the bona fide endogenous ligand so far, and further investigations are required to definitively solve this critical issue.
Initially, 9CRA was identified as an agonist for RXRs, but it is not an RXR-selective compound because it displays a high affinity for all three RARs Dawson, 2004) . The most widely use rexinoids are SR11237, LG100268, and LGD1069, which is currently used in therapy (see below) . Nevertheless, no rexinoid with apparent subtype selectivity has been identified so far. This issue seems very challenging because all residues that constitute the LBP of the three RXRs are highly conserved. RXR-selective antagonists have also been identified (for reviews, see Thacher . Interestingly, among the reported RXR antagonists, LG100754 has been described as an RXR antagonist that can transcriptionally activate on its own both RXR␣-RAR␣ and RXR␣-PPAR␥ heterodimers, suggesting a particular conformation of RXR LBD induced by this compound .
Expression and Function of RXRs
Disparities are observed in the expression pattern of the RXRs. RXR␤ is widely distributed and can be detected in almost every tissue Yu et al., 1991; . RXR␣ is predominantly expressed in liver, kidney, epidermis, and intestine and is the major RXR in skin (Mangelsdorf et al., 1990 . RXR␥ is mostly restricted to the muscle and certain parts of the brain as well as to the pituitary (Mangelsdorf et In addition to the fact that RXRs are heterodimeric partners of multiple nuclear receptors regulating various developmental and metabolic processes, this RXR distribution suggests that RXRs play critical roles in a wide range of these processes. To address the issue of the RXR functional role in vivo, knockout of all three RXRs has been performed in the mouse (for comprehensive reviews, see Kastner . This informative genetic approach showed that the inactivation of the RXR␣ gene has more severe consequences than the ablation of RXR␤ and RXR␥. The loss of RXR␣ is lethal during fetal life Sucov et al., 1994) . The major observed defect is a hypoplasia of the myocardium that seems to be the principal cause of 762 animal death that occurs by cardiac failure at approximately embryonic day 14.5. Furthermore, fetuses lacking RXR␣ have ocular malformations . Importantly, both defects due to RXR␣ inactivation are similar to those observed in vitamin A-deficient fetuses and in RAR␤ Ϫ/Ϫ ␥ Ϫ/Ϫ double mutants . This suggests that RXR␣ is essential in the transduction of a retinoid signal required for myocardial development and ocular morphogenesis, supporting the idea that RXR␣ is involved in retinoid signaling in vivo. This view is also supported by the fact that RXR␣ is involved in the mediation of a teratogenic effect due to administration of exogenous retinoids. Indeed, treatment of embryos with vitamin A induces limb truncations that do not occur in RXR␣ mutants (Sucov et al., 1995) .
The ablation of RXR␤ led to ϳ50% in utero lethality . Those mice that survive seem normal except that the males are sterile and exhibit testicular defects and abnormal spermatid maturation, leading to defects of spermatozoa. Also RXR␤ mutation leads to abnormal lipid metabolism in Sertoli cells, suggesting functional interactions of RXR␤ with other nuclear receptors that control lipid metabolism (Mascrez et al., 2004) .
RXR␥-null mutants seem normal and are fertile . Nevertheless, these mice have higher serum levels both of thyroxine and thyroid-stimulating hormone and an increased metabolic rate compared with wild-type animals . This is in agreement with the expression of RXR␥ in the thyrotrope cells of the anterior pituitary gland.
In addition to the above single-null mutant mice, mutants lacking a pair or more of RXR subtypes or RXR/ RAR double-null mutants were generated. For instance RXR␤␥ double mutants exhibit locomotor deficiencies due to a dysfunction in the dopamine signaling pathway (Krezel et al., 1998) . Given the number of combinations, a complete description of the results, mainly found by Pierre Chambon's group, is not possible here (for recent reviews, see . Together these results demonstrate that the RXR-RAR heterodimers transduce in vivo the retinoid signal and that specific heterodimers are involved in given developmental processes. On the other hand, the differentiation of the F9 murine embryonal carcinoma cells by retinoic acid has been investigated in the context of various such combinations of mutants . These cellular studies led to the conclusion that distinct RXR-RAR heterodimers have different roles in the control of target genes in F9 cells. Moreover, it has been shown that RXR␣ is specifically required for the correct differentiation of retinoid-treated F9 cells .
Nevertheless, all these studies have shown that some functional redundancy exists between RXRs. In addition, owing to the in utero lethality, observed, for instance, in RXR␣ inactivation, analyses of the specific RXR functions at postnatal stages and in adult animals are not possible using classic knockout experiments. To elude these limitations, conditional knockouts were generated. The selective disruption of RXR␣ from hepatocytes led to the conclusion that RXR␣ is a crucial functional partner for many other nuclear receptors such as LXR␣, PXR, FXR, CAR␤, and PPAR␣ (Wan et al., 2000) . Without RXR␣, all these receptors cannot activate their target genes efficiently. Hence, the absence of RXR␣ from the liver affects many metabolic processes. Furthermore, using an elegant method based on a cell typespecific expression of an inducible Cre recombinase that is only active in the presence of tamoxifen, somatic null mutation of RXR␣ has been specifically performed in epidermal keratinocytes of the adult mouse (Li et al. . Because VDR-null mutant mice display a similar phenotype, it is likely that RXR␣ exerts its role in the skin through the VDR-RXR␣ heterodimer.
Lastly, to address the critical issue of whether the transcriptional activity of RXR␣ is required for its function in vivo or whether its heterodimerization capacity is the principal role of RXR␣, mice were generated in which either most of the terminal A/B domain or helix 12 of the LBD, that harbors AF-1 and AF-2 function, respectively, was lacking (Mascrez et al., 2001; . Eliminating AF-2 function resulted in a number of (but not all) abnormalities similar to those exhibited by RXR␣ null mice, suggesting that the RXR␣ transactivation function was required for the developmental functions of the RXR␣-RAR heterodimers. Animals expressing truncated RXR␣ lacking AF-1 function also displayed some similar or less severe abnormalities, showing that AF-2 seems to be more important than AF-1 for the function of RXR during embryonic development.
Therapy and Diseases
Although the mechanisms of action of rexinoids in cancer therapy and chemoprevention are poorly understood, clinical examination of these compounds is in progress. Strikingly, the synthetic rexinoid LGD1069 (bexarotene, Targretin) was recently approved for treating refractory advanced-stage cutaneous T-cell lymphoma (Heald, ., 2004) . On the other hand, the existence of a RAR-independent RXR signaling pathway that allows the differentiation of cells may also be a potential target in cancer research (Benoit et al., 1999; Altucci et al., 2005) . Indeed, a cross-talk between rexinoids and protein kinase A signaling pathways has been demonstrated that can induce differentiation of retinoic acid-resistant t(15:17) leukemic promyeloblasts. This example highlights the anticancer potential of the combination of rexinoids with other signaling drugs.
Drugs (Chawla et al., 2001) . Notably, RXRs are obligate heterodimer partners for nuclear receptors related to lipid physiology, namely PPARS, LXRs, and FXRs. Furthermore, the observation that liver-specific inactivation of RXR in mice results in abnormalities in all metabolic pathways substantiates the pleiotropic role of this receptor (Wan et al., 2000) . Because such permissive heterodimers can be activated by rexinoids, RXRselective ligands have promising potential as clinical agents in the field of metabolic syndrome. For example, heterodimerization with RXR is required for PPAR␥ activity including the expression of genes involved in the uptake of glucose in muscle, lipid metabolism, and energy expenditure . PPAR␥ has been implicated in several important metabolic diseases. The antidiabetic agents, thiazolidinediones (TZDs) selectively bind to PPAR␥ and are widely used as drugs that improved insulin sensitivity in patients with insulin resistance syndrome despite some associated adverse effects (Lehmann et Functional assays Differentiation of 3T3-L1 cells to adipocytes measured by the accumulation of triglyceride produced within the cytoplasm of the adipocyte {Mm} 33, 62, 63 ; induction of apoptosis (associated with RAR␣ activation) in leukemia cell lines {Hs} 38, 64 ; primitive endodermal differentiation and morphological differentiation in F9 murine embryonal carcinoma cell line {Mm} 65, 66 Mutant phenotype Knockout mice have hypoplasia of the myocardium, which leads to animal death due to cardiac failure at around embryonic day 14.5; animals also have ocular malformation {Mm} ͓knockout͔ Functional assays Differentiation of 3T3-L1 cells to adipocytes measured by the accumulation of triglyceride produced within the cytoplasm of the adipocyte {Mm} 34, 52, 53 ; induction of apoptosis (associated with RAR␣ activation) in leukemia cell lines {Hs} 38, 54 Mutant phenotype
Male sterility due to defective spermatogenesis, abnormal lipid metabolism in Sertoli cells and behavioral defects {Mm} ͓knockout͔ Biologically important isoforms RXR␥1 {Mm}: differs from RXR␥ 2 in the A/B domain 45, 46 ; RXR␥2 {Mm} 45, 46 . Tissue distribution RXR␥1 is expressed in the brain and muscle, whereas RXR␥ 2 is highly expressed in both cardiac and skeletal muscles {Mm, Rn} ͓Northern blot, in situ hybridization, Western blot͔ 45, [47] [48] [49] Mutant phenotype Knockout mice have metabolic and behavioral defects {Mm} ͓knockout͔ [50] [51] [52] [53] [54] 
